- Home
- GYRE vs NMM Comparison
GYRE vs NMM Comparison
Compare GYRE & NMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NMM
- Stock Information
- Founded
- GYRE 2002
- NMM 2007
- Country
- GYRE United States
- NMM Greece
- Employees
- GYRE N/A
- NMM N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NMM Marine Transportation
- Sector
- GYRE Health Care
- NMM Consumer Discretionary
- Exchange
- GYRE Nasdaq
- NMM Nasdaq
- Market Cap
- GYRE 897.1M
- NMM 959.8M
- IPO Year
- GYRE N/A
- NMM 2007
- Fundamental
- Price
- GYRE $7.42
- NMM $37.53
- Analyst Decision
- GYRE
- NMM Strong Buy
- Analyst Count
- GYRE 0
- NMM 1
- Target Price
- GYRE N/A
- NMM $80.00
- AVG Volume (30 Days)
- GYRE 253.7K
- NMM 95.9K
- Earning Date
- GYRE 08-12-2025
- NMM 08-19-2025
- Dividend Yield
- GYRE N/A
- NMM 0.53%
- EPS Growth
- GYRE N/A
- NMM N/A
- EPS
- GYRE 0.02
- NMM 11.16
- Revenue
- GYRE $100,643,000.00
- NMM $1,319,623,000.00
- Revenue This Year
- GYRE $21.04
- NMM N/A
- Revenue Next Year
- GYRE $89.64
- NMM $7.93
- P/E Ratio
- GYRE $93.77
- NMM $3.38
- Revenue Growth
- GYRE N/A
- NMM 0.28
- 52 Week Low
- GYRE $6.11
- NMM $28.37
- 52 Week High
- GYRE $19.00
- NMM $65.89
- Technical
- Relative Strength Index (RSI)
- GYRE 39.71
- NMM 43.84
- Support Level
- GYRE $7.26
- NMM $39.87
- Resistance Level
- GYRE $8.00
- NMM $39.41
- Average True Range (ATR)
- GYRE 0.49
- NMM 1.25
- MACD
- GYRE -0.07
- NMM -0.28
- Stochastic Oscillator
- GYRE 10.36
- NMM 0.00
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.